Khloris Biosciences

Khloris Biosciences is a private, pre-clinical stage biotech developing first-in-class iPSC-based cancer vaccines and cell therapies. The company's platform leverages a large, diverse biobank of human iPSC lines to create vaccines designed to elicit a broad anti-tumor immune response. Khloris has established a key strategic collaboration with Leaps by Bayer, Bayer's investment arm, to advance its anti-cancer vaccine programs, positioning it to address significant unmet needs in oncology and cardiology.

Platform utilizing human induced pluripotent stem cells (iPSCs) for developing cancer vaccines, cell therapies for cardiovascular disease, and drug discovery tools. Core assets include an iPSC-based cancer vaccine platform and a large, diverse biobank of human iPSC lines.

Khloris operates in the highly competitive fields of cancer vaccines and iPSC-based therapies. It faces competition from numerous biotechs and pharma companies developing mRNA, peptide, and viral vector-based cancer vaccines, as well as other firms developing iPSC-derived cell therapies for oncology and cardiology. Its differentiation lies in its unique whole-iPSC vaccine approach and its extensive iPSC biobank.